MicroRNAs as Biomarkers and Therapeutic Targets in Disease
A special issue of Genes (ISSN 2073-4425). This special issue belongs to the section "Molecular Genetics and Genomics".
Deadline for manuscript submissions: closed (20 December 2021) | Viewed by 2502
Special Issue Editor
Interests: genetic and epigenetic mechanisms contributing to metastasis and cancer therapy resistance; non-coding RNAs as regulators of cancer stemness, EMT and cancer therapy resistance; CRISPR/Cas9 genome editing system in cancer research and treatment; immune checkpoint proteins as new targets for anti-cancer therapy
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Non-coding RNAs (ncRNAs), including microRNAs (miRNAs), long non-coding RNAs (lncRNAs) and circular RNAs (circRNAs), make up the majority of the human transcriptome and have been hot topics in recent years. MiRNAs are small, endogenous non-coding RNAs that bind to complementary sequences in their target mRNAs to modulate the expression of target mRNAs. LncRNAs competitively sponge miRNAs as competing endogenous RNAs through base complementarity, indirectly controlling the effects of miRNAs on their target genes. CircRNAs interact with diverse molecules (including miRNAs) to regulate gene expression and cell function. NcRNAs play crucial roles in diseases (including cancer). NcRNAs are promising biomarkers for the diagnosis, staging, classification, and prognosis of diseases, and for monitoring clinical response to therapy. Therefore, ncRNAs can be considered as novel biomarkers and therapeutic targets in diseases.
In this Special Issue, we are inviting reviews, perspectives, and original research articles focused on the functions, regulatory mechanisms, and clinical applications of all kinds of ncRNAs (especially miRNAs). We also welcome studies that highlight new technologies, new analysis platforms, new animal models, and new manipulation tools for the study of ncRNAs.
Prof. Dr. Peixin Dong
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Genes is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- miRNA
- lncRNA
- circRNA
- biomarker
- therapeutic target
